FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 240 filers reported holding FATE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,051,342 | -55.5% | 495,916 | 0.0% | 0.21% | -79.5% |
| Q2 2023 | $2,360,560 | -16.5% | 495,916 | 0.0% | 1.02% | +34.0% |
| Q1 2023 | $2,826,721 | -73.0% | 495,916 | -52.2% | 0.76% | -71.5% |
| Q4 2022 | $10,465,913 | -55.0% | 1,037,256 | 0.0% | 2.67% | -51.5% |
| Q3 2022 | $23,245,000 | -9.6% | 1,037,256 | 0.0% | 5.51% | -5.2% |
| Q2 2022 | $25,703,000 | – | 1,037,256 | – | 5.81% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |